Humanigen: Rises on manufacturing agreement for COVID-19 therapy

Humanigen

17/05/2021 15:34

** Drug developer's shares  HGEN.O  rise 3% to $18.28 
    ** HGEN enters agreement with contract development and
manufacturing organization Chime Biologics to help produce its
COVID-19 therapy candidate lenzilumab for commercial sale
outside the United States  urn:newsml:reuters.com:*:nBw4gvlLva
    ** Sale is subject to the receipt of regulatory
authorizations or approvals in regions including Europe, United
Kingdom, India and Brazil - HGEN
    ** Commercial product is expected to be available in 2022 -
Co
    ** "We think this is a good strategic move since many places
outside the U.S. are still in need of treatments for COVID-19
and are behind the US with their vaccination rollout," Cantor
Fitzgerald says
     ** Brokerage expects sales of ~$1 bln in first twelve
months depending on regulatory approvals
     ** HGEN had gained 1.4% YTD, up to last close

    
    

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))